Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $12.31 in the last session, down -1.20% from day before closing price of $12.46. In other words, the price has decreased by -$1.20 from its previous closing price. On the day, 1.9 million shares were traded. AMLX stock price reached its highest trading level at $12.56 during the session, while it also had its lowest trading level at $11.91.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.70 and its Current Ratio is at 13.70. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 30 ’25 when Klee Justin B. sold 29,975 shares for $14.38 per share. The transaction valued at 430,952 led to the insider holds 3,325,301 shares of the business.
Mazzariello Gina sold 8,828 shares of AMLX for $128,669 on Sep 30 ’25. The Chief Legal Officer now owns 148,141 shares after completing the transaction at $14.58 per share. On Sep 30 ’25, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 10,558 shares for $14.65 each. As a result, the insider received 154,650 and left with 280,430 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1351878912 and an Enterprise Value of 1013823872. Its current Enterprise Value per Revenue stands at -1524.547 whereas that against EBITDA is -6.467.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.28, which has changed by 0.7510668 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $16.96, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is -6.64%, while the 200-Day Moving Average is calculated to be 68.61%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 1.72M shares per day over the past 3-months and 1412510 shares per day over the past 10 days. A total of 109.77M shares are outstanding, with a floating share count of 92.67M. Insiders hold about 15.62% of the company’s shares, while institutions hold 71.15% stake in the company. Shares short for AMLX as of 1760486400 were 9616175 with a Short Ratio of 5.60, compared to 1757894400 on 8774952. Therefore, it implies a Short% of Shares Outstanding of 9616175 and a Short% of Float of 9.7799994.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$1.26 and -$1.75 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.18, with 7.0 analysts recommending between -$0.76 and -$1.64.
